# A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)

> **NCT00160667** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 152 (actual)

## Conditions studied

- Neuralgia, Postherpetic

## Interventions

- **DRUG:** Placebo
- **DRUG:** Brivaracetam

## Key facts

- **NCT ID:** NCT00160667
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10-11
- **Primary completion:** 2006-01-05
- **Final completion:** 2006-01-05
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2019-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00160667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00160667, "A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00160667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*